Onco Therapies Ltd, a wholly owned subsidiary of Strides Arcolab Ltd (Strides), has announced that it has received two more Abbreviated New Drug Application (ANDA) approvals for Fludarabine Phosphate Injection and Idarubicin Hydrochloride Injection.
The company has got approvals from the US Food and Drugs Administration (USFDA) and the combined market for the two drugs is about $20 million.
Fludarabine is a chemotherapy drug used to treat chronic lymphocytic leukaemia (a type of cancer of the white blood cells) in adults while Idarubicin belongs to the group of cancer-fighting medications known as antineoplastics. Idarubicin is used alone or in combination with other antineoplastic medications to treat leukaemia.